Results 221 to 230 of about 94,964 (299)
The role of pre-existing left-sided valvular heart disease in the prognosis of patients with acute myocardial infarction. [PDF]
Muzafarova T, Motovska Z.
europepmc +1 more source
Lineage labeling with zebrafish hand2 Cre and CreERT2 recombinase CRISPR knock‐ins
Abstract Background The ability to generate endogenous Cre recombinase drivers using CRISPR‐Cas9 knock‐in technology allows lineage tracing, cell type‐specific gene studies, and in vivo validation of inferred developmental trajectories from phenotypic and gene expression analyses. This report describes endogenous zebrafish hand2 Cre and CreERT2 drivers
Zhitao Ming+14 more
wiley +1 more source
Management of multiple valve replacement operations for a young patient with hypereosinophilic syndrome and valvular heart disease: a case report. [PDF]
Kado Y+9 more
europepmc +1 more source
Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis
Abstract COVID‐19 vaccines have been linked to myocarditis, which, in some circumstances, can be fatal. This systematic review aims to investigate potential causal links between COVID‐19 vaccines and death from myocarditis using post‐mortem analysis.
Nicolas Hulscher+3 more
wiley +1 more source
Gut Microbiome and Its Role in Valvular Heart Disease: Not a "Gutted" Relationship. [PDF]
Nayak G+7 more
europepmc +1 more source
Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu+3 more
wiley +1 more source
Challenges and Opportunities in Valvular Heart Disease: From Molecular Mechanisms to the Community. [PDF]
Aikawa E+4 more
europepmc +1 more source
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler+4 more
wiley +1 more source